Posted on 08/12/2009 in Pharmaceutical Company Product News Lilly's therapy Zyprexa (olanzapine) has been indicated for two different treatment options in adolescent patients, it has emerged.
The Food and Drug Administration (FDA) has recommended Zyprexa as a therapy option in tablet form for the treatment of schizophrenia and the manic or mixed episodes associated with bipolar I disorder in youngsters aged 13 to 17 years old.
Additionally, the drug's label has been updated to include recommendations for its use in a comprehensive treatment programme in paediatric patients with the disorders.
Part of this treatment may include psychological, educational and social interventions.
Cherri Miner, neuroscience senior medical director at Lilly, stated: "Customers have been asking for data from controlled studies in these populations and now, with this information added to our label, we can help physicians make informed treatment decisions."
Earlier this month, Lilly made its latest educational booklet - entitled The Value of Medicine, Improving Health, Improving Life - available to its client base. Other news stories from 08/12/2009
Read more in the Zenopa News Archive
How this news is generated
|
